

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 November 2023 (02.11.2023)



(10) International Publication Number
WO 2023/212219 A1

(51) International Patent Classification:

C07D 487/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/496 (2006.01) *A61P 35/04* (2006.01)
A61K 31/498 (2006.01) *C07D 471/04* (2006.01)
A61K 31/4985 (2006.01) *C07D 491/048* (2006.01)
A61K 31/517 (2006.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2023/020235

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(22) International Filing Date:

27 April 2023 (27.04.2023)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/336,078 28 April 2022 (28.04.2022) US
63/381,482 28 October 2022 (28.10.2022) US

(71) Applicant: **XINTHERA, INC.** (legal representatives of the deceased inventor) [US/US]; 12730 High Bluff Drive, Suite 300, San Diego, California 92130 (US).

(72) Inventors: **HOFFMAN, Robert L.**; 12730 High Bluff Drive, Suite 300, San Diego, California 92130 (US). **VA, Porino Jinjo**; 12730 High Bluff Drive, Suite 300, San Diego, California 92130 (US). **PINCHMAN, Joseph Robert**; 12730 High Bluff Drive, Suite 300, San Diego, California 92130 (US). **DONG, Qing**; 12730 High Bluff Drive, Suite 300, San Diego, California 92130 (US).

(72) Inventor: **KALDOR, Stephen W.** (deceased).

(74) Agent: **TANNER, Lorna, L.** et al.; SHEPPARD MULLIN RICHTER & HAMPTON LLP, 650 Town Center Drive, 10th Floor, Costa Mesa, California 92626-1993 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: TRICYCLIC PARP1 INHIBITORS AND USES THEREOF

(57) Abstract: Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.



WO 2023/212219 A1